Across TCGA pan-cancer cohorts, RFPL3S RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RFPL3S’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where RFPL3S RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RFPL3S is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

CHOL, LUSC, and THCA are the cancer types where RFPL3S tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RFPL3S RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	Male	All	+1.091	<.001	5	view →
LUSC	Male	All	+0.438	<.001	4	view →
THCA	All	All	−0.132	.002	4	view →
KIRC	All	All	+0.077	.004	3	view →
LIHC	Male	All	+0.096	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RFPL3S RNA expression & survival · all RFPL3S data types